Said liposome is an amphoteric liposome.
Desirably, the liposome is a paucilamellar vesicle.
The invention provides a dry powder formulation which contains a lyophilized DNA/liposome complex, a lyophilized RNA/liposome complex, a lyophilized oligonucleotide/liposome complex or a lyophilized protein/liposome complex.
The antibody-modified liposome may comprise: (A) a liposome; (B) serum albumin bound to the liposome; (C) a spacer bound to serum albumin present on the surface of the liposome; and (D) an antibody bound to the spacer.
The therapeutic compositions of the present invention include liposome entrapped irinotecan in which the liposome can contain any of a variety of neutral or charged liposome-forming compouds and cardiolipin.
The invention relates to a method for initiating the controlled rupture of the membrane a biocompatible liposome, often called a furtive liposome, thereby releasing the liposome content to the environment thereof.
The liposome composition contains an osmotic gradient across the liposome lipid bilayer, wherein the osmolarity of the external medium is higher than the osmolarity of the liposome inner medium.
The liposomal delivery complex generally comprises a liposome, an antibody, and a connecting moiety which binds the Fc region of the antibody for binding the liposome to the antibody.
Also disclosed are methods of predicting the fusogenicity of an amphoteric liposome at a given pH, formulating an amphoteric liposome and loading an amphoteric liposome with a cargo moiety.
The methods include administration of a therapeutic liposome containing an active agent, followed by a administration of an attacking liposome that induces release of the agents from the therapeutic liposome.
The mepartricin is encapsulated within a liposome.
The liposome is composed as described above.
The vesicle can be a liposome.